Efficacy of AIDS vaccine strategies in nonhuman primates.
Since only a limited number of vaccines can be tested for efficacy in phase 3 studies in humans, a filter is needed allowing selection of the most promising ones. Although differences between HIV infection in humans and simian immunodeficiency virus infection in nonhuman primates (NHP) might limit the predictive value of these models, comparative efficacy studies in NHPs could facilitate ranking of vaccine candidates. While various forms of protein vaccines failed to induce consistent protection, live-attenuated vaccines, DNA vaccines and viral vector vaccines provided various levels of protection in NHPs. However, variability in the experimental models limits the conclusions that can be drawn with respect to the relative efficacy of vaccines not tested in the same experiment. Therefore, better standardization is an urgent necessity in order to exploit the full potential of nonhuman primate models in AIDS vaccine development.
Uberla
Klaus
K
Department of Molecular and Medical Virology, Ruhr-University Bochum, 44780 Bochum, Germany. klaus.ueberla@ruhr-uni-bochum.de
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D004195:Disease Models, Animal; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D011323:Primates; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D016915:AIDS Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic